HK Stock Market Move | LEADS BIOLABS-B (09887) rose more than 6%. The company is expected to be included in the Hang Seng Composite Index.

LEADS BIOLABS-B(09887) rose more than 6%, at the time of this report, it rose by 6.11% to HK$65.1 with a turnover of HK$186.588 million. On the news front, on February 13th, Hang Seng Index Company announced the quarterly review results of the Hang Seng Index series as of December 31, 2025, with Vervantis Biotechnology being included in the Hang Seng Composite Index. The changes will be implemented after the market close on March 6, 2026, and will take effect from March 9, 2026. At that time, the Shanghai and Shenzhen Stock Exchanges will adjust the scope of eligible stocks for investment in Hong Kong stocks through the Stock Connect program accordingly. According to China International Capital Corporation research report, Vervantis Biotechnology may be included in the Stock Connect program as it meets a series of criteria including market capitalization, liquidity, and listing time. Recently, Vervantis Biotechnology announced that the first patient in the phase Ib/II clinical study of VeliLinx (PD-L1/4-1BB bispecific antibody Opatasomab monoclonal antibody, LBL-024) for the treatment of recurrent or metastatic triple-negative breast cancer has successfully received treatment. The open-label, multicenter phase Ib/II clinical study, led by Professor Yin Yongmei from Jiangsu Province People's Hospital, is being simultaneously conducted in multiple hospitals nationwide. The trial aims to evaluate the efficacy and safety of Opatasomab monoclonal antibody alone or in combination with albumin-bound paclitaxel in the treatment of patients with recurrent or metastatic triple-negative breast cancer.